Printer Friendly

Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011.

Mycoplasma pneumoniae is a major cause of community-acquired pneumonia among children and adults (1). Macrolides are recommended for treatment of M. pneumoniae pneumonia (1).

High rates of macrolide-resistant M. pneumoniae have been reported in China (>90%) and Japan (87.1%) (2,3). In Europe, reports of macrolide resistance have ranged from 3% in Germany to 9.8% in France (4,5). In the United States, 8.2% of M. pneumonia-positive specimens identified during 2007-2010 were resistant to macrolides (6). M. pneumoniae confer macrolide resistance primarily as a result of nucleotide substitutions at specific positions in the V domain of the 23S rRNA gene. Mutations at nt 2063 (A2063T/G), 2064 (A2064G), and 2617 (C2617A/G) have been shown to be associated with increased MICs to macrolides, including erythromycin, azithromycin, and clarithromycin (2,3,7,8). Use of macrolides to treat macrolide-resistant M. pneumoniae result in lower effectiveness and increased clinical severity compared with macrolide-susceptible M. pneumoniae (9). In contrast to macrolides, resistance to quinolones or tetracyclines among clinical isolates of M. pneumoniae has not been reported, although development of such resistance after use of increased concentrations of fluoroquinolones or doxycycline has been demonstrated in in vitro settings (10,11).

The Public Health Ontario Laboratory, which is the reference microbiology laboratory for the province of Ontario, provides molecular testing for detection of M. pneumoniae for hospitalized and ambulatory patients. In August 2011, the positivity rate for specimens with M. pneumoniae increased to 9.3% and peaked in December 2011 to 17.5%. During the same time, increased numbers of cases of M. pneumoniae were reported throughout Europe. In response to the increased positivity rate and lack of data for Canada on macrolide resistance in M. pneumoniae, we investigated antimicrobial drug susceptibility profiles of M. pneumoniae detected during February 2010-January 2012 by using molecular methods. In addition, available M. pneumoniae isolates were characterized by sequencing the P1 gene to determine the prevalence of circulating types in Ontario, Canada (12,13).

The Study

During February 1, 2010-January 31, 2012, a total of 2,898 respiratory specimens were tested for M. pneumoniae and Chlamydophila pneumoniae by using a multiplex testing real-time assay (ProPneumo-1 Assay; Gen-Probe Inc., San Diego, CA, USA). A total of 96 specimens were positive for M. pneumoniae, and 16 specimens were positive for C. pneumoniae. Among M. pneumoniae-positive specimens, 67 (70%) and 29 (30%) were from the upper and lower respiratory tract, respectively. Six (6.0%) specimens were collected from children < 4 years of age, 48 (50%) from persons 5-20 years of age, 19 (20%) from persons 21-40 years of age, 19 (20%) from persons 41-60 years of age, and 23 (24%) from persons >65 years of age. All M. pneumoniae-PCR positive specimens were cultured and 42 (44%) of the 96 primary specimens yielded positive isolates.

Nested PCR amplification and DNA sequencing of the partial 23S rRNA gene were performed to detect mutations at nucleotide positions 2063, 2064, 2067, 2617 in the 23S rRNA gene, which are associated with macrolide resistance (2,8). In addition to macrolide resistance, molecular determinants of fluoroquinolones (gyrA and parC) and tetracycline (16S rRNA) resistance were also analyzed (10,11).

For macrolide resistance, 91 (95%) of 96 specimens were amplified and analyzed for mutations. Mutations that have been associated with macrolide resistance were found in 11 (12.1%) of the 91 specimens (Table 1). Of the 11 isolates with a mutant genotype, 10 (90.9%) contained a mutation at nucleotide position 2063 (A2063G), and 2 (18.2%) specimens had a mutation at position 2064 (A2064G). In 4 isolates, a mixed population of wild type and mutant at position 2063 were identified on sequence chromatograms. One specimen had wild type and co-mutations at positions 2063 and 2064. None of the specimens contained any mutations at positions A2067 or C2617.

In addition to macrolide resistance, molecular determinants of fluoroquinolone and tetracycline resistance in M. pneumoniae were examined. A previous report showed that substitutions at position 99 (83 for Escherichia coli) of gyrA and positions 81, 83, and 87 (78, 80, and 84 for E. coli) of parC were associated with fluoroquinolone resistance (10). In our study, none of the isolates contained any mutations that have been associated with fluoroquinolones resistance. Similarly, amplification and sequencing of 16S rRNA gene regions encompassing the tetracycline binding site did not show any mutations at positions 968 (T968C) and 1193 (G1193A), which have been shown to be associated with tetracycline resistance among M. pneumoniae (11).

Typing of M. pneumoniae isolates (42/96) by amplification and Sanger sequencing of almost the entire P1 adhesion gene was performed by using primer pairs ADH1/2, ADH3/4, and ADH2BF/R, which amplify 3 fragments of [approximately equal to] 2,280, 2,580 and 767 bp, respectively (13). Sequencing reactions were performed in both directions by using the Big Dye Terminator Cycle Sequencing Ready Reaction DNA Sequencing Kit in an ABI 3730 or 3750 automated sequencer (Applied Biosystems, Foster City, CA, USA).

P1 gene sequencing identified 6-11 variable number tandem repeat AGT sequences. Using sequence typing and comparing homology of nucleotide and amino acid sequences to reference sequences, we found that 16 (38%) isolates belonged to type 1 and shared high homology at nucleotide (99.7%-99.9%) and amino acid (99.5%-99.9%) levels. Seven of the P1 type 1 isolates had a point mutation in E179K, and 3 of these isolates also had a second mutation Q1232E compared with the type 1 reference strain (M129). Twenty-six (62%) isolates were characterized as type 2 and were differentiated within 3 variants (Table 2). Among 5 resistant isolates that were typed, 3 belonged to type 1 and 2 belonged to type 2.


In this study, 12.1% of M. pneumoniae-positive specimens contained mutations that are associated with macrolide resistance, and most (90.9%) specimens had a mutation at nt 2063. This finding is not surprising because this mutation has been shown to be predominant among macrolide-resistant M. pneumoniae and has been associated with high-level resistance (erythromycin MIC >64 mg/L) (2,3,14). None of the specimens contained any mutations at positions 2067 or 2617 because mutations at these positions are rare. Previous studies have shown reduced efficacy rate of macrolides for treating infections with M. pneumoniae isolates containing 3 mutations (7,9).

Typing of the P1 gene showed no clear association between macrolide-resistant isolates and specific subtype because 3 of the 5 resistant isolates belonged to type 1 and the remaining 2 belonged to type 2; there was no evidence of clonality. This finding is consistent with reports in which macrolide-resistant M. pneumoniae isolates of both types were found (2,5,8). However, according to a recent study in China, where macrolide-resistant M. pneumoniae is highly prevalent (>90%), most isolates were type 1 (15).

None of the M. pneumoniae isolates contained any gyrA gene mutations associated with fluoroquinolone resistance or any 16S rRNA gene mutations associated with tetracycline resistance. These findings are consistent with those of a study in which none of the isolates were resistant to fluoroquinolones or minocycline (2).

Dr Eshaghi is a research technologist at the Public Health Ontario Laboratory with extensive experience in molecular microbiology. His research interests are characterization of antimicrobial drug resistance and respiratory viral infections.

DOI: 10.3201/eid1909.121466


(1.) Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53:617-30.

(2.) Okada T, Morozumi M, Tajima T, Hasegawa M, Saskata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012; 55:1642 9.

(3.) Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in Mycoplasma pnemoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010; 51:189-94.

(4.) Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother. 2009; 64:52-8.

(5.) Dumke R, Von Baum H, Luck PC, Jacobs E. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect. 2010; 16:613-6. j.1469-0691.2009.02968.x

(6.) Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J. 2012; 31:409-10. INF.0b013e318247f3e0

(7.) Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in paediatric patients with CAP. Antimicrob Agents Che mother. 2008; 52:348-50.

(8.) Matsuoka M, Narita M, Okazaki N, Ohya H, Yamzaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004; 48:4624-30.

(9.) Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resitant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009; 15:380-3.

(10.) Gruson D, Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and in Mycoplasma hominis. Antimicrob Agents Chemother. 2005; 49:1190-3. AAC.49.3.1190-1193.2005

(11.) Degrange S, Renaudin H, Charron A, Pereyre S, Bebear C, Bebear CM. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother. 2008; 61:1390-2.

(12.) Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol. 2007; 45:3534-9.

(13.) Dorigo-Zetsma JW, Wilbrink B, Dankert J, Zaat SA. Mycoplasma pneumoniae P1 type 1- and type 2-specific sequences within the P1 cytadhesin gene of individual strains. Infect Immun. 2001; 69:5612-8.

(14.) Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneuomniae, Israel. Emerg Infect Dis. 2011; 17:1079-82. http://dx.doi. org/10.3201/eid1706.101558

(15.) Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, et al. Antibiotic sensitivity of40 Mycoplasmapneuomniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob Agents Chemother. 2012; 56:1108-9. AAC.05627-11

Address for correspondence: Samir N. Patel, Public Health Ontario Laboratory-Toronto, 81 Resources Rd, Toronto, Ontario M9P 3T1, Canada; email:

Author affiliations: Ontario Agency for Health Protection and Promotion, Toronto, Ontario, Canada (A. Eshaghi, N. Memari, P. Tang, R. Olsha, D.J. Farrell, D.E. Low, J.B. Gubbay, S.N. Patel); University of Toronto, Toronto (D.J. Farrell, D.E. Low, J.B. Gubbay, S.N. Patel); Mount Sinai Hospital, Toronto (D.E. Low, J.B. Gubbay); and The Hospital for Sick Children, Toronto (J.B. Gubbay)
Table 1. Macrolide-resistant Mycoplasma pneumoniae identified in
Ontario, Canada, 2010-2011 *

                                       Specimen       Specimen
Patient     ID no.     Age, y/sex   collection date    source

1         H72992-11       43/F        2011 Aug 8        SPT
2         C706158-11      10/M        2011 Aug 25        NP
3         K35611 -11      38/F        2011 Sep 1         NP
4         C751048-11      44/F        2011 Sep 8        BAL
5         P54752-11       42/M        2011 Oct 6         NP
6         P54912-11       12/M        2011 Oct 13        NP
7         M29279-11       3/F         2011 Dec 9         NP
8         N223472-11      5/M         2011 Dec 14       BAL
9         N223473-11      5/M         2011 Dec 14       BAL
10        C34899-12       10/F        2012 Jan 20        NP
11        C63502-12       37/F        2012 Jan 23        BW

                          Substitution in 23s rRNA

Patient     ID no.     A2063   A2064   A2067   C2617

1         H72992-11     A/G     A/G      A       C
2         C706158-11    A/G      A       A       C
3         K35611 -11     G       A       A       C
4         C751048-11     G       A       A       C
5         P54752-11      G       A       A       C
6         P54912-11     A/G      A       A       C
7         M29279-11      G       A       A       C
8         N223472-11     G       A       A       C
9         N223473-11     A       G       A       C
10        C34899-12      G       A       A       C
11        C63502-12     A/G      A       A       C

* ID, idenitifcation; SPT, sputum; NP, nasopharyngeal swab; BAL,
bronchoavelor lavage; BW, bronchial washing.

Table 2. Typing of Mycoplasma pneumoniae isolates by P1 adhesion gene,
Ontario, Canada, 2010-2011 *

P1                                         GenBank       Nucleotide
gene     No.                              accession      homology,
type   isolates   Variant   Reference   no. ([dagger])       %

1         16        NA        M129         U00089.2      99.7-99.9

2         8         NA       Mp1842       AF290002.1     99.6-99.9
          3         2a       Mpn309       AP012303.1     99.8-99.9
          8         2b        T-103       AB691539.1     99.5-99.9

          7         2c        P033        JN048891.1      99.8-100

P1                Amino acid   Nonsynonymous mutations
gene     No.      homology,    compared with reference
type   isolates       %             (no. isolates)

1         16      99.5-99.9     E179K (7), D559N (1),
                                      Q1232E (4)
2         8       99.5-99.8      S841L, E962D, I1302V
          3       99.5-99.6      Y210N (1), T837N (3)
          8       99.5-99.9    S1516P: 6 isolates had a
                                deletion at 1244-QTNS-
          7        99.7-100             V1411E

P1                 No. VTR    No. drug-
gene     No.         AGT      resistant
type   isolates   sequences   isolates

1         16        7-11          3

2         8         7-11          1
          3           6           0
          8          7-9          1

          7          7-9          0

* VTR, variable tandem repeat. NA, not applicable (strains M129 and
Mp1842 are considered prototypes representative for types 1 and 2).

([dagger]) The sequences of the P1 gene generated in this study have
been deposited in GenBank (accession nos. KF154740-KF154759).
COPYRIGHT 2013 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:DISPATCHES
Author:Eshaghi, AliReza; Memari, Nader; Tang, Patrick; Olsha, Romy; Farrell, David J.; Low, Donald E.; Gubb
Publication:Emerging Infectious Diseases
Article Type:Report
Geographic Code:1CONT
Date:Sep 1, 2013
Previous Article:R292K substitution and drug susceptibility of influenza A(H7N9) viruses.
Next Article:Hepatitis E virus genotype 4, Nanjing, China, 2001-2011.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |